Product Details
Before clinical trials, it is essential to study the potential toxicity of candidate drugs in order to identify any adverse effects. The purpose of preclinical safety assessment is generally to determine the toxic effects on target organs, dose dependency, the relationship between compound exposure, and to identify potential reversibility. All these data will be used to establish a safe starting dose for clinical trials and determine parameters for monitoring potential adverse reactions during clinical monitoring. However, if conducting large-scale toxicity and safety studies in GLP (Good Laboratory Practice) facilities without initial knowledge of the effective dose and safety dose of the test substance may lead to dose adjustments and repetition of subsequent efficacy tests, which may result in increased risks and significant escalation of research costs.